Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy

Diabetologia

Volumn 51, Issue 11, 2008, Pages 2100-2107

  Jorsal, A ^a   Tarnow, L ^a   Flyvbjerg, A ^b   Parving, H H ^b,c   Rossing, P ^a   Rasmussen, L M ^d  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Rigshospitalet   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular events; Diabetes; Diabetic nephropathy; End stage renal disease; Glomerular filtration rate; Mortality; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN;

ADULT; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS;

EID: 53549102739     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-1123-8     Document Type: Article

References (42)

1. WS Simonet DL Lacey CR Dunstan 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319
2. E Tsuda M Goto S Mochizuki 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis Biochem Biophys Res Commun 234 137 142
3. A Tomoyasu M Goto N Fujise 1998 Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor Biochem Biophys Res Commun 245 382 387
4. P Olesen T Ledet LM Rasmussen 2005 Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha Diabetologia 48 561 568
5. M Schoppet N Al Fakhri FE Franke 2004 Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis J Clin Endocrinol Metab 89 4104 4112
6. JG Emery P McDonnell MB Burke 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 273 14363 14367
7. UM Malyankar M Scatena KL Suchland TJ Yun EA Clark CM Giachelli 2000 Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells J Biol Chem 275 20959 20962
8. M Schoppet KT Preissner LC Hofbauer 2002 RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function Arterioscler Thromb Vasc Biol 22 549 553
9. P Olesen K Nguyen L Wogensen T Ledet LM Rasmussen 2007 Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin Am J Physiol Heart Circ Physiol 292 H1058 H1064
10. SE Heinonen P Leppänen I Kholová 2007 Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia and hypercholesterolemia Circ Res 101 1058 1067
11. M Vaccarezza R Bortul R Fadda M Zweyer 2007 Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats Med Chem 4 387 391
12. WS Browner LY Lui SR Cummings 2001 Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women J Clin Endocrinol Metab 86 631 637
13. ST Knudsen CH Foss PL Poulsen NH Andersen CE Mogensen LM Rasmussen 2003 Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications Eur J Endocrinol 149 39 42
14. M Schoppet AM Sattler JR Schaefer M Herzum B Maisch LC Hofbauer 2003 Increased osteoprotegerin serum levels in men with coronary artery disease J Clin Endocrinol Metab 88 1024 1028
15. S Jono Y Ikari A Shioi 2002 Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease Circulation 106 1192 1194
16. P Clancy L Oliver R Jayalath P Buttner J Golledge 2006 Assessment of a serum assay for quantification of abdominal aortic calcification Arterioscler Thromb Vasc Biol 26 2574 2576
17. S Dellegrottaglie J Sanz S Rajagopalan 2006 Molecular determinants of vascular calcification: a bench to bedside view Curr Mol Med 6 515 524
18. LM Rasmussen L Tarnow TK Hansen HH Parving A Flyvbjerg 2006 Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients Eur J Endocrinol 154 75 81
19. DV Anand A Lahiri E Lim D Hopkins R Corder 2006 The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects J Am Coll Cardiol 47 1850 1857
20. J Hjelmesaeth T Ueland A Flyvbjerg 2006 Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients J Am Soc Nephrol 17 1746 1754
21. T Ueland R Jemtland K Godang 2004 Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction J Am Coll Cardiol 44 1970 1976
22. Parving H-H, Mauer M, Ritz E (2004) Diabetic nephropathy. In: Brenner BM (ed) Brenner and Rector's the kidney, 7th edn. Saunders, Boston, pp 1777-1818
23. L Tarnow PH Groop S Hadjadj 2008 European rational approach for the genetics of diabetic complications EURAGEDIC: patient populations and strategy Nephrol Dial Transplant 23 161 168
24. B Feldt-Rasmussen B Dinesen M Deckert 1985 Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy Scand J Clin Lab Invest 45 539 544
25. J Bröchner-Mortensen P Rödbro 1976 Selection of routine method for determination of glomerular filtration rate in adult patients Scand J Clin Lab Invest 36 35 45
26. MA Pfeffer K Swedberg CB Granger 2003 Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 759 766
27. A-S Astrup WY Kim L Tarnow 2008 Relation of left ventricular function, mass, and volume to NT-proBNP in type 1 diabetic patients Diabetes Care 31 968 970
28. KL Tyson JL Reynolds R McNair Q Zhang PL Weissberg CM Shanahan 2003 Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification Arterioscler Thromb Vasc Biol 23 489 494
29. M Scatena C Giachelli 2002 The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis Trends Cardiovasc Med 12 83 88
30. N Bucay I Sarosi CR Dunstan 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1260 1268
31. M Takemoto K Yokote M Nishimura 2000 Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis Arterioscler Thromb Vasc Biol 20 624 628
32. LM Rasmussen T Ledet 1993 Aortic collagen alterations in human diabetes mellitus. Changes in basement membrane collagen content and in the susceptibility of total collagen to cyanogen bromide solubilisation Diabetologia 36 445 453
33. L Heickendorff T Ledet LM Rasmussen 1994 Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque Diabetologia 37 286 292
34. L Niskanen O Siitonen M Suhonen MI Uusitupa 1994 Medial artery calcification predicts cardiovascular mortality in patients with NIDDM Diabetes Care 17 1252 1256
35. S Lehto L Niskanen M Suhonen T Ronnemaa M Laakso 1996 Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus Arterioscler Thromb Vasc Biol 16 978 983
36. LM Rasmussen T Ledet 2005 Osteoprotegerin and diabetic macroangiopathy Horm Metab Res 37 Suppl 1 90 94
37. C Lorz A Benito-Martin A Boucherot 2008 The death ligand TRAIL in diabetic nephropathy J Am Soc Nephrol 19 904 914
38. GD Xiang HL Sun LS Zhao 2007 Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients Diabetes Res Clin Pract 76 199 206
39. F Galluzzi S Stagi R Salti 2005 Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status Eur J Endocrinol 153 879 885
40. GD Xiang L Xu LS Zhao L Yue J Hou 2006 The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes Diabetes 55 2126 2131
41. M Abedin T Omland T Ueland 2007 Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study) Am J Cardiol 99 513 518
42. DV Anand E Lim D Darko 2007 Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers J Am Coll Cardiol 50 2218 2225